Atlas Trials

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Clinical trial NCT00441155 · COMPLETED

Trial details

NCT number
NCT00441155
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Gastrointestinal Stromal Tumors
Start date
2006-11-01
Primary completion
2011-01-01
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.